Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL2357736 | 1.00 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL25265024 | 1.00 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL28554884 | 1.00 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL27982709 | 0.94 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL1354089 | 0.94 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL4864252 | 0.94 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL6849522 | 0.94 | ALDH1A1 (0.50) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL36480 | 0.94 | MEN1 (0.46) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL23827344 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL21639727 | 0.88 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600628-B2 | Inorganic hollow nanocoils and method of manufacturing the same | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2026-04-14 | — | — | US | disclosed |
| CN-117265451-A | Corrosion-resistant, high-hardness and submicron-grade hard alloy coating material and preparation process thereof | 中南大学 | 2023-12-22 | — | — | CN | disclosed |
| US-20230029603-A1 | INORGANIC HOLLOW NANOCOILS AND METHOD OF MANUFACTURING THE SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-02-02 | — | — | US | disclosed |
| CN-115133026-A | Sodium-rich vanadium sodium phosphate, preparation method thereof and sodium-ion battery | 江苏正力新能电池技术有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-105885682-A | Flame-retardant film coating and preparation method thereof | 铜陵方正塑业科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-8674149-B2 | Oxidative mono-halogenation of methane | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110201841-A1 | OXIDATIVE MONO-HALOGENATION OF METHANE | DOW GLOBAL TECHNOLOGIES LLC | 2011-08-18 | — | — | US | disclosed |
| WO-2010062427-A2 | OXIDATIVE MONO-HALOGENATION OF METHANE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20080213400-A1 | Combinations of Chromium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080181970-A1 | Combinations of Vanadium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-07-31 | — | — | US | disclosed |
| CN-1694862-A | Method for producing acrylic acid from propane | ARKEMA (FR) | 2005-11-09 | — | — | CN | disclosed |
| US-20050233946-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A | 2005-10-20 | — | — | US | disclosed |
| US-20050233947-A1 | Combinations of chromium or vanadium with antidiabetics | FINE STUART A | 2005-10-20 | — | — | US | disclosed |
| US-20050187144-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A (US) | 2005-08-25 | — | — | US | disclosed |
| US-6852760-B1 | Compositions and methods for treatment for glucose metabolism disorders | AKESIS PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1113804-A2 | COMBINATIONS OF CHROMIUM OR VANADIUM WITH ANTIDIABETICS FOR GLUCOSE METABOLISM DISORDERS | Akesis Pharmaceuticals, Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001003700-A1 | COMBINATION OF CHROMIUM AND VANADIUM FOR GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000057721-A2 | EDIBLE SOLIDS FOR TREATMENT OF GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000057729-A2 | BEVERAGES FOR TREATMENT OF GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000015211-A2 | COMPOSITIONS OF CHROMIUM OR VANADIUM WITH ANTIDIABETICS FOR GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600628-B2 | Inorganic hollow nanocoils and method of manufacturing the same | YBX1, HBZ, YBX3 | MEN1 3966/4885ALDH1A1 1482/4885TSHR 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.